RGEN:NASDAQ
Repligen Corp
131,20 $
arrow_upward
+4,68%(+5,87) 1D
9 հնս, 14:33:52 GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RGEN...
Open
127,49 $
High
132,24 $
Low
127,42 $
Mkt. cap
7,41 մլրդ
Avg. vol.
1,22 մլն
Volume
828,08 հզր
P/E ratio
143,98
52-wk high
175,57 $
52-wk low
100,99 $
EPS
0,91 $
Beta
1,09
Shares outstanding
56,41 մլն
No. of employees
2 հզր
Open
127,49 $
High
132,24 $
Low
127,42 $
Mkt. cap
7,41 մլրդ
Avg. vol.
1,22 մլն
Volume
828,08 հզր
P/E ratio
143,98
52-wk high
175,57 $
52-wk low
100,99 $
EPS
0,91 $
Beta
1,09
Shares outstanding
56,41 մլն
No. of employees
2 հզր
Analyst outlook
Analyst Ratings
Based on 15 analysts giving stock ratings to RGEN in the past 3 months
Strong Buy
Buy
12
Hold
3
Sell
0
12 month forecast
Based on 15 Wall Street analysts offering 12 month price targets for RGEN in the last 3 months.
Highest
Current 131,20 $
208,00 $ (+58,54%)
Average
165,17 $ (+25,90%)
Lowest
140,00 $ (+6,71%)
News stories
From sources across the web
DirectorsTalk Interviews
·
1 օր առաջ
Repligen Corporation (RGEN) Stock Analysis: Unlocking a 43.98% Upside in Bioprocessing Innovation
Profile
Repligen Corporation is an American life sciences company that develops and manufactures products used in biological drug manufacturing. The company is headquartered in Waltham, Massachusetts, and is listed on the Nasdaq under the symbol RGEN. Wikipedia
About Repligen Corp
CEOTony J. Hunt
Employees2 հզր
Founded1981
HeadquartersՈւոլթեմ, Մասսաչուսեթս, Միացյալ Նահանգներ
Sector-
Websiterepligen.com
AI content may include mistakes. Learn more